ANTHEM
Anthem Biosciences Limited
Each stock's 10,000-path forecast, rendered as light.
Anthem Biosciences Limited (ANTHEM) Stock Analysis & Case Study
Is ANTHEM a good buy? The data-driven verdict.
Anthem Biosciences Limited (ANTHEM) trades at ₹841,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, Anthem Biosciences Limited (ANTHEM) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 79.8× earnings, ROE of 22.3%, a 58% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ANTHEM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ANTHEM ranks against the 2,373 companies in our screener
- ANTHEM's market cap of 47,367 Cr ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ANTHEM's book value of ₹54 ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ANTHEM's promoter holding of 71.4% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ANTHEM's 3-year profit (PAT) growth of 21.0% ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ANTHEM's 3-year revenue growth of 26.0% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ANTHEM's debt-to-equity ratio of 0.02x is lower than 94% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ANTHEM overvalued? ANTHEM P/E vs peers
ANTHEM trades at 79.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ANTHEM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.0y of ANTHEM history (14%/yr drift, 30%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ANTHEM 2027 | ₹606 | ₹895 | ₹1,323 | +6% |
| ANTHEM 2028 | ₹553 | ₹953 | ₹1,643 | +13% |
| ANTHEM 2029 | ₹513 | ₹1,014 | ₹2,005 | +21% |
| ANTHEM 2030 | ₹488 | ₹1,080 | ₹2,390 | +28% |
| ANTHEM 2031 | ₹471 | ₹1,149 | ₹2,806 | +37% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ANTHEM goes up, or doubles?
The bull case for ANTHEM
- ANTHEM's return on equity of 22.3% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ANTHEM's return on capital employed of 30.4% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,005.
The bear case & risks
- ANTHEM's P/E of 79.8x is lower than 14% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 15.5× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹513.
ANTHEM volatility & expected range, how bumpy is the ride?
Over the last 1.0 years ANTHEM compounded at 14%/year with annualized volatility of 30%. That volatility implies a 1-year 80% range of ₹606-₹1,323, the honest backbone behind any single price target.
ANTHEM price forecast, the full 60-month probability fan
ANTHEM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ANTHEM hits common targets within the simulated horizon?
Full multi-horizon detail on the ANTHEM price target & forecast page.
ANTHEM Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ANTHEM scores 6/8, mixed financial health.
ANTHEM MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy ANTHEM with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 27.34% | 3.7× |
| Zerodha | 27.35% | 3.7× |
| Groww | 27.39% | 3.7× |
| Dhan | 27.35% | 3.7× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 27.39% | 3.7× |
| PocketfulCHEAPEST | 27.32% | 3.7× |
| Fyers | 27.78% | 3.6× |
| Anand Rathi | 27.35% | 3.7× |
| Bajaj Broking | 30.00% | 3.3× |
| Share India | 27.39% | 3.7× |
Compare every broker on the ANTHEM MTF page.
About Anthem Biosciences Limited: sector, index & market-cap context
Anthem Biosciences Limited (ANTHEM) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹47,367 Cr. See more stocks on our screener.
How the ANTHEM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Anthem Biosciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ANTHEM analysis, FAQs
Is Anthem Biosciences Limited (ANTHEM) a good buy?
On the numbers, Anthem Biosciences Limited (ANTHEM) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 79.8× earnings, ROE of 22.3%, a 58% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ANTHEM overvalued or undervalued?
ANTHEM trades at 79.8× earnings, expensive versus the ~22× long-run Nifty average.
What is the ANTHEM share price target for 2031?
ANTHEM's probability-weighted 2031 median target is ₹1,149, with an 80% range of ₹471-₹2,806 (10,000-path Monte-Carlo).
What is the probability ANTHEM doubles in 5 years?
The modelled probability of ANTHEM reaching ₹1,682 (2×) within 5 years is 29%.
What is the bull case for ANTHEM?
ANTHEM's return on equity of 22.3% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. ANTHEM's return on capital employed of 30.4% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in ANTHEM?
ANTHEM's P/E of 79.8x is lower than 14% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 15.5× price-to-book means most of the value is intangible/expectations, not assets on the books.